Author: admin

Non-Alcoholic Fatty Liver Disease Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Pfizer, Eli Lilly and Company, CohBar, Inc., Roche, Amgen

The Non-Alcoholic Fatty Liver Disease Market Forecast report offers an in-depth understanding of the Non-Alcoholic Fatty Liver Disease, historical and forecasted epidemiology as well as the Non-Alcoholic Fatty Liver Disease market trends in the 7MM.

DelveInsight’s “Non-Alcoholic Fatty Liver Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Non-Alcoholic Fatty Liver Disease, historical and forecasted epidemiology as well as the Non-Alcoholic Fatty Liver Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Non-Alcoholic Fatty Liver Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Non-Alcoholic Fatty Liver Disease Market Forecast

 

Some of the key facts of the Non-Alcoholic Fatty Liver Disease Market Report: 

  • The Non-Alcoholic Fatty Liver Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In September 2022, Inventiva and Chia Tai-Tianqing Pharmaceutical Group entered into a licensing and collaboration agreement to develop and commercialize lanifibranor, if approved, for the treatment of nonalcoholic steatohepatitis and potentially other metabolic diseases in mainland China, Hong Kong, Macau, and Taiwan
  • In May 2022, Hepion Pharmaceuticals entered into a clinical collaboration with HepQuant, a Denver-based, privately held company with novel, proprietary investigational technology for evaluating liver function and health in patients with chronic liver diseases. Hepion will incorporate the HepQuant ‘’SHUNT’’ test into a dedicated Phase IIb clinical trial in presumed NASH F3 subjects, initiating in Q3 of this year
  • In January 2022, LISCure Biosciences entered into a research collaboration agreement with Mayo Clinic for new drug development for rare liver diseases
  • The existing pipeline for NASH comprises a wide array of medications. FXR agonists, FGF21 stimulants, FGF19 analogs, glucagon-like peptide-1 (GLP-1) agonists, peroxisome proliferator-activated receptor (PPAR) regulators, THR-β agonists, and several others are among the prominent classes for this condition.
  • According to American Liver Foundation (n.d.), NAFLD is the most common chronic liver condition in the United States. It’s estimated that about 25% of adults in the U.S. have NAFLD. Of those with NAFLD, about 20% have NASH (5% of adults in the US). Most people with NAFLD have simply fatty live
  • According to the study conducted by Foschi et al. (2019), titled, “Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study,” the prevalence of non-alcoholic fatty liver disease (NAFLD) was 0.46 (0.41 to 0.51) vs. 0.22 (0.21 to 0.24) in citizens with than in those without altered liver enzymes
  • Key Non-Alcoholic Fatty Liver Disease Companies: Inventiva Pharma, Eli Lilly and Company, Madrigal Pharmaceuticals, Inc., Intercept Pharmaceuticals, 89bio, Inc., Novo Nordisk A/S, NeuroBo Pharmaceuticals Inc, Novo Nordisk A/S, J2H Biotech, Haisco Pharmaceutical, Madrigal Pharmaceuticals, Altimmune, Inc., GlaxoSmithKline, Axcella Health, Inc, AstraZeneca, Gannex Pharma Co., Ltd., Dexa Medica Group, Boehringer Ingelheim, Can-Fite BioPharma, Rivus Pharmaceuticals, Inc., Regeneron Pharmaceuticals, MediciNova, and others
  • Key Non-Alcoholic Fatty Liver Disease Therapies: Lanifibranor, Tirzepatide, MGL-3196, Semaglutide, Obeticholicacid (OCA), Pegozafermin, DA-1241, NNC0194 0499, J2H-1702, HSK31679, Resmetirom, Pemvidutide, GSK4532990, AXA1125, AZD9550, 2mg of ASC41, Proliverenol, Survodutide, Namodenoson, HU6, ALN-HSD, MN-001, and others
  • The Non-Alcoholic Fatty Liver Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non-Alcoholic Fatty Liver Disease pipeline products will significantly revolutionize the Non-Alcoholic Fatty Liver Disease market dynamics.

 

Non-Alcoholic Fatty Liver Disease Overview

Non-alcoholic fatty liver disease (NAFLD) is an umbrella term that encompasses the entire spectrum of fatty liver disease, from simple steatosis to more progressive steatosis with associated hepatitis, fibrosis, cirrhosis, and in some cases hepatocellular carcinoma.

 

Get a Free sample for the Non-Alcoholic Fatty Liver Disease Market Report –

https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-market

 

Non-Alcoholic Fatty Liver Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Non-Alcoholic Fatty Liver Disease Epidemiology Segmentation:

The Non-Alcoholic Fatty Liver Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Non-Alcoholic Fatty Liver Disease
  • Prevalent Cases of Non-Alcoholic Fatty Liver Disease by severity
  • Gender-specific Prevalence of Non-Alcoholic Fatty Liver Disease
  • Diagnosed Cases of Episodic and Chronic Non-Alcoholic Fatty Liver Disease

 

Download the report to understand which factors are driving Non-Alcoholic Fatty Liver Disease epidemiology trends @ Non-Alcoholic Fatty Liver Disease Epidemiology Forecast

 

Non-Alcoholic Fatty Liver Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Alcoholic Fatty Liver Disease market or expected to get launched during the study period. The analysis covers Non-Alcoholic Fatty Liver Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Non-Alcoholic Fatty Liver Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Non-Alcoholic Fatty Liver Disease Therapies and Key Companies

  • Lanifibranor: Inventiva Pharma
  • Tirzepatide: Eli Lilly and Company
  • MGL-3196: Madrigal Pharmaceuticals, Inc.
  • Obeticholicacid (OCA): Intercept Pharmaceuticals
  • Pegozafermin: 89bio, Inc.
  • Semaglutide: Novo Nordisk A/S
  • DA-1241: NeuroBo Pharmaceuticals Inc
  • NNC0194 0499: Novo Nordisk A/S
  • J2H-1702: J2H Biotech
  • HSK31679: Haisco Pharmaceutical
  • Resmetirom: Madrigal Pharmaceuticals
  • Pemvidutide: Altimmune, Inc.
  • GSK4532990: GlaxoSmithKline
  • AXA1125: Axcella Health, Inc
  • AZD9550: AstraZeneca
  • 2mg of ASC41: Gannex Pharma Co., Ltd.
  • Proliverenol: Dexa Medica Group
  • Survodutide: Boehringer Ingelheim
  • Namodenoson: Can-Fite BioPharma
  • HU6: Rivus Pharmaceuticals, Inc.
  • ALN-HSD: Regeneron Pharmaceuticals
  • MN-001: MediciNova

 

Discover more about therapies set to grab major Non-Alcoholic Fatty Liver Disease market share @ Non-Alcoholic Fatty Liver Disease Treatment Market

 

Non-Alcoholic Fatty Liver Disease Market Strengths

  • Growing research activities and multiple clinical trials ongoing for NASH, suggests that the number of drugs is being developed, that will strengthen the market

 

Non-Alcoholic Fatty Liver Disease Market Opportunities

  • Lucrative opportunities for the market growth in United States, owing to presence of large pool of patients suffering from NASH

 

Scope of the Non-Alcoholic Fatty Liver Disease Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Non-Alcoholic Fatty Liver Disease Companies: Inventiva Pharma, Eli Lilly and Company, Madrigal Pharmaceuticals, Inc., Intercept Pharmaceuticals, 89bio, Inc., Novo Nordisk A/S, NeuroBo Pharmaceuticals Inc, Novo Nordisk A/S, J2H Biotech, Haisco Pharmaceutical, Madrigal Pharmaceuticals, Altimmune, Inc., GlaxoSmithKline, Axcella Health, Inc, AstraZeneca, Gannex Pharma Co., Ltd., Dexa Medica Group, Boehringer Ingelheim, Can-Fite BioPharma, Rivus Pharmaceuticals, Inc., Regeneron Pharmaceuticals, MediciNova, and others
  • Key Non-Alcoholic Fatty Liver Disease Therapies: Lanifibranor, Tirzepatide, MGL-3196, Semaglutide, Obeticholicacid (OCA), Pegozafermin, DA-1241, NNC0194 0499, J2H-1702, HSK31679, Resmetirom, Pemvidutide, GSK4532990, AXA1125, AZD9550, 2mg of ASC41, Proliverenol, Survodutide, Namodenoson, HU6, ALN-HSD, MN-001, and others
  • Non-Alcoholic Fatty Liver Disease Therapeutic Assessment: Non-Alcoholic Fatty Liver Disease current marketed and Non-Alcoholic Fatty Liver Disease emerging therapies
  • Non-Alcoholic Fatty Liver Disease Market Dynamics: Non-Alcoholic Fatty Liver Disease market drivers and Non-Alcoholic Fatty Liver Disease market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Non-Alcoholic Fatty Liver Disease Unmet Needs, KOL’s views, Analyst’s views, Non-Alcoholic Fatty Liver Disease Market Access and Reimbursement 

 

To know more about Non-Alcoholic Fatty Liver Disease companies working in the treatment market, visit @ Non-Alcoholic Fatty Liver Disease Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Non-Alcoholic Fatty Liver Disease Market Report Introduction

2. Executive Summary for Non-Alcoholic Fatty Liver Disease

3. SWOT analysis of Non-Alcoholic Fatty Liver Disease

4. Non-Alcoholic Fatty Liver Disease Patient Share (%) Overview at a Glance

5. Non-Alcoholic Fatty Liver Disease Market Overview at a Glance

6. Non-Alcoholic Fatty Liver Disease Disease Background and Overview

7. Non-Alcoholic Fatty Liver Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Non-Alcoholic Fatty Liver Disease 

9. Non-Alcoholic Fatty Liver Disease Current Treatment and Medical Practices

10. Non-Alcoholic Fatty Liver Disease Unmet Needs

11. Non-Alcoholic Fatty Liver Disease Emerging Therapies

12. Non-Alcoholic Fatty Liver Disease Market Outlook

13. Country-Wise Non-Alcoholic Fatty Liver Disease Market Analysis (2019–2032)

14. Non-Alcoholic Fatty Liver Disease Market Access and Reimbursement of Therapies

15. Non-Alcoholic Fatty Liver Disease Market Drivers

16. Non-Alcoholic Fatty Liver Disease Market Barriers

17.  Non-Alcoholic Fatty Liver Disease Appendix

18. Non-Alcoholic Fatty Liver Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non-Alcoholic Fatty Liver Disease Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Pfizer, Eli Lilly and Company, CohBar, Inc., Roche, Amgen

SubShave Launches Revolutionary Subscription Sharing Service Offering Major Discounts on Top Digital Platforms

SubShave, a new affiliate of GamsGo, which is set to transform how users access and share premium digital services. The innovative platform allows customers to share subscriptions to leading streaming and software services such as Spotify, Tidal Plus, Netflix, Crunchyroll, MAX, YouTube Premium, Microsoft Office, IPTV PRO, IPTV 18+, Deezer Family, SkyShowtime, Disney+, paramount+ and more. With SubShave, users can enjoy these services at a fraction of the price that anyone else offers. Discover this innovative approach at www.subshave.com.

Instant Access and Seamless Subscription Management

SubShave is committed to providing a fast, seamless user experience. Key to this is their real-time delivery feature, which ensures that subscribers can access services immediately after payment — there is no lag between payment and play. This instant delivery mechanism is complemented by a similarly swift ‘Quick Reset Passkey’ function, which allows users to reset their passkeys instantly on the subscription page without any manual steps or delays.

Secured and Safe Transactions

Understanding the importance of security in today’s digital world, SubShave safeguards all transactions with SSL encryption. This ensures that all personal and payment information remains secure, providing peace of mind for users engaging in financial transactions online.

Around-the-Clock Customer Support

SubShave distinguishes itself through its dedication to customer satisfaction, which is why the platform offers 24/7 live support. This service ensures that any issues can be addressed promptly at any time of day, guaranteeing a smooth and enjoyable user experience. Whether subscribers have questions about setting up an account, managing subscriptions, or troubleshooting, SubShave’s support team is always just a click away.

Finding the Perfect Co-Subscriber

One of SubShave’s standout features is its ability to pair users with the ideal co-subscriber. This is facilitated through an innovative matching system that prioritizes pairing subscribers from the same country, enhancing compatibility and reliability. This feature allows users to enjoy premium digital services at a fraction of the cost by sharing subscriptions with others who have similar interests and needs.

Guaranteed Satisfaction

To assure subscribers of their commitment to quality and satisfaction, SubShave offers a flexible refund policy. Subscribers can request a refund within a period ranging from 1 to 20 days, depending on the terms of their subscription. This refund guarantee underscores SubShave’s confidence in the value and reliability of its service.

How SubShave Works

SubShave operates by allowing users to sign up and choose a subscription plan from a variety of premium services. Users then enter into a pool where they are matched with other interested subscribers in their country. Once matched, the group can access the service at a reduced rate, thanks to the shared subscription model. Each member has their own login, maintained securely by SubShave, ensuring individual access remains uninterrupted and private.

Benefits to Subscribers

The benefits of using SubShave are numerous. Subscribers can save significantly on monthly expenses for digital services, while still enjoying all the features of premium subscriptions. The platform’s secure environment and quick access mean that users can enjoy their favorite shows, music, and software without delays and with complete peace of mind. Moreover, the live support and easy management tools make maintaining and modifying subscriptions simple and hassle-free.

Join the Community

To start saving on premium subscriptions, potential users can visit SubShave’s website to learn more about the available services and sign up for an account. The signup process is straightforward, and users can begin searching for suitable co-subscribers immediately.

About SubShave

SubShave, affiliated with GamsGo, is at the forefront of subscription sharing, offering a platform where users can economically share access to premium digital services. The service is designed to make high-quality digital content accessible at a lower cost, promoting both community building and substantial savings.

Media Contact
Company Name: SubShave
Contact Person: Mohnish
Email: Send Email
Country: United Kingdom
Website: www.subshave.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: SubShave Launches Revolutionary Subscription Sharing Service Offering Major Discounts on Top Digital Platforms

From Zero to Hero: Transform Credit Future with HighScoreNow.com’s Comprehensive Tools

In today’s financial landscape, having a good credit score is more important than ever. Whether you’re looking to buy a home, finance a car, or even rent an apartment, your credit score can make or break your chances of approval. That’s where HighScoreNow comes in. We’re here to give you the tools and resources you need to achieve a better credit future, starting with access to credit scores, credit monitoring, and so much more.

Why Choose HighScoreNow?

When it comes to your credit, settling for less is not an option. You deserve a comprehensive view of your credit standing, and that’s exactly what HighScoreNow delivers. Unlike other credit monitoring services that only provide scores and reports from one bureau, we give you access to all three – Equifax, Experian, and TransUnion.

With HighScoreNow, you can see the full picture of your credit health. Our platform is designed to be user-friendly and accessible, allowing you to view your scores and reports 24/7 from any device, whether you’re at home or on the go. We believe that staying informed about your credit should be convenient and easy, and that’s the experience we strive to provide.

Credit Reports & Scores: Your Key to Financial Success

Your credit reports and scores are the foundation of your financial well-being. They hold the key to your credit history, including your payment patterns, credit utilization, and any negative marks such as collections or bankruptcies. Understanding what’s in your credit reports and how it affects your scores is crucial to making informed financial decisions.

With HighScoreNow, you can take a deep dive into your credit reports from all three bureaus. Our platform breaks down the information in a way that’s easy to understand, highlighting the factors that are helping or hurting your scores. By identifying areas for improvement, you can take targeted action to boost your credit standing.

But we don’t just stop at credit reports. We also provide you with your credit scores from all three bureaus, giving you a complete picture of your credit health. Knowing your scores is essential when it comes to applying for loans, credit cards, or even renting an apartment. With HighScoreNow, you’ll never be caught off guard by a surprise score or denial.

24/7 Credit Monitoring: Your Credit Watchdog

Your credit is a living, breathing entity that can change at any moment. A new account opened in your name, a missed payment, or even a hard inquiry from a lender can all have an impact on your scores. That’s why 24/7 credit monitoring is so important, and it’s a key feature of HighScoreNow’s services.

Our advanced monitoring system keeps a constant watch on all three of your credit reports, 365 days a year. If we detect any suspicious activity or changes to your reports, we’ll notify you immediately through our credit alerts. This could be anything from a new account opened in your name to a hard inquiry from a lender you don’t recognize.

By staying informed about changes to your credit, you can take swift action if necessary. This could mean disputing errors on your credit reports, identifying potential fraud, or even catching a forgotten payment before it has a chance to damage your scores. With HighScoreNow’s 24/7 credit monitoring, you can rest easy knowing that your credit is in good hands.

Credit Education: Empowering You to Succeed

At HighScoreNow, we believe that credit education is just as important as credit monitoring. After all, what good is having access to your scores and reports if you don’t know how to interpret them? That’s why we’ve created a comprehensive credit education center to help you understand the ins and outs of credit scoring and reporting.

Our credit FAQ section covers a wide range of topics, from the basics of how credit scores are calculated to more advanced strategies for building and maintaining excellent credit. We break down complex concepts into easy-to-understand language, so you can feel confident in your ability to navigate the world of credit.

But we don’t just stop at the basics. We also provide tips and insights on how to improve your credit scores over time, such as paying down high balances, disputing errors on your credit reports, and maintaining a healthy mix of credit types. With HighScoreNow’s credit education resources, you’ll have the knowledge and tools you need to succeed.

Your Partner in Credit Success

At HighScoreNow, we’re more than just a credit monitoring service – we’re your partner in credit success. We understand that achieving your credit goals takes time and effort, but we’re here to support you every step of the way.

Whether you’re just starting out on your credit journey or you’re a seasoned pro, HighScoreNow has something to offer. Our comprehensive credit monitoring, educational resources, and user-friendly platform are designed to help you take control of your credit future and achieve your financial goals.

So why wait? Sign up for HighScoreNow today and start taking advantage of all the benefits we have to offer. With access to all three credit reports and scores, 24/7 monitoring, and a wealth of educational resources, you’ll be well on your way to the credit score of your dreams. Let us help you unlock your full financial potential and achieve the future you deserve.

The HighScoreNow Difference

At HighScoreNow, we pride ourselves on being different from other credit monitoring services. Here are just a few of the ways we stand out:

  1. Comprehensive coverage: We provide access to credit scores and reports from all three major bureaus – Equifax, Experian, and TransUnion. This means you get the full picture of your credit health, not just a partial view.
  2. 24/7 monitoring: Our advanced monitoring system keeps a constant watch on your credit reports, alerting you to any suspicious activity or changes. This allows you to stay on top of your credit and take action if necessary.
  3. Easy-to-use platform: Our user-friendly platform makes it easy to access your scores and reports from any device, at any time. We believe that staying informed about your credit should be convenient and stress-free.
  4. Comprehensive education: Our credit education center provides a wealth of resources to help you understand credit scoring, reporting, and improvement strategies. We empower you with the knowledge you need to succeed.
  5. Personalized support: We’re more than just a faceless service – we’re your partner in credit success. Our team is here to support you every step of the way, whether you have questions about your scores or need guidance on improving your credit.

Taking the First Step

Taking control of your credit future can seem daunting, but with HighScoreNow, it’s easier than ever. By signing up for our service, you’re taking the first step toward a better credit future.

Here’s what you can expect when you sign up for HighScoreNow:

  1. Immediate access to your credit scores and reports from all three bureaus
  2. 24/7 credit monitoring to alert you to any changes or suspicious activity
  3. A user-friendly platform that makes it easy to access your information from any device
  4. Comprehensive credit education resources to help you understand and improve your scores
  5. Personalized support from our team of credit experts

So what are you waiting for? Take the first step toward a better credit future with HighScoreNow. Sign up today and start enjoying the peace of mind that comes with knowing your credit is in good hands.

Media Contact
Company Name: HighScoreNow
Email: Send Email
City: Irvine
State: California
Country: United States
Website: https://www.highscorenow.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: From Zero to Hero: Transform Credit Future with HighScoreNow.com\’s Comprehensive Tools

Alive Christians Website Shares Faith Resources With The Body of Christ Globally

Alive Christias has lots of great resources for Christian believers around the world. As the focus of the site is training believers to be everything that God wants them to be the founder, Apostle Quinson Thomas, has made it his top priority to ensure that believers around the world have the necessary tools, insights, and revelations for effective ministry. And in this regard, he has shared, online, many tools and documents for believers.

The first tool is the Bible questions and answers. This allows believers to know the answers to many popular questions that may be hard to find by simply perusing the scriptures. Here believers can learn how long Adam and Eve lived and how long the Lord Jesus lived, and many other answers to questions that they may have.

At AliveChrisians.com, visitors also learn about the website’s initiative to teach piano to communities throughout the United States and indeed around the world. This is said to be an effort to give much-needed help to churches, which very often need musicians for their worship services. These piano lessons are available there and to start, the site offers free introductory lessons.

In addition to biblical questions and answers, there are also biblical definitionson the site. Site visitors will learn what blasphemy and salvation mean. They will also learn what sin is and what holiness truly means according to the Word of God.

The site also features many Psalms. The Psalms are written mostly by King David and there are many powerful truths to inspire and encourage believers there, and so the site offers the Psalms for visitors to read, or watch videos concerning the Psalms so that they can build their Bible knowledge and gather powerful insights.

Also, there’s a host of hymns from many different centuries that are sure to inspire faith and help believers in times of worship to the Lord. The hymns are from the times of the Reformation and go forward into the 20th century.

Lastly, site visitors will also learn what the Bible says about healing and how it is available for believers by faith today. As the Lord Jesus was in His earthly ministry healing people, site visitors will see that the healing ministry is still for today, and if applicable, learn the steps to walk in the healing ministry of the Lord in their everyday lives.

Media Contact
Company Name: Alive Christians Website
Contact Person: Quinson Thomas
Email: Send Email
Country: United States
Website: www.alivechristians.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Alive Christians Website Shares Faith Resources With The Body of Christ Globally

Unlocking Potential: Psychological Testing Services Now Available in Troy, MI

In today’s fast-paced world, understanding oneself and maximizing personal potential is more crucial than ever.

Addressing this need, Bright Pine Behavioral Health a leading provider of counseling and psychological services, is excited to announce the launch of its new location for its comprehensive counseling and psychological testing services in Troy, MI.  

They offer invaluable insights into an individual’s cognitive abilities, personality traits, emotional well-being, and behavioral patterns. Whether for personal growth, academic or career advancement, or addressing mental health concerns, their psychological services serve as powerful tools for self-discovery and development.

Bright Pine Behavioral Health team of experienced psychologists and mental health professionals specialize in administering a wide range of psychological tests tailored to meet the unique needs of each client. From IQ and aptitude assessments to personality inventories and diagnostic evaluations, our services are designed to provide accurate and actionable information to support clients on their journey toward personal and professional fulfillment.

“Our goal is to empower individuals to better understand themselves, overcome challenges, and unlock their full potential. Whether you’re a student seeking academic accommodations, professional navigating career choices, or simply someone looking to gain deeper insight into yourself, our comprehensive testing services are here to help.”

At Bright Pine Behavioral Health client well-being and confidentiality are top priorities. Each assessment and counseling session is conducted with the utmost professionalism, respect, and sensitivity to individual needs. Our team takes pride in providing a supportive and nonjudgmental environment where clients can feel comfortable and secure throughout the testing process. Visit the website at https://www.brightpinepsychology.com/troy/ to get the knowledge about counseling in troy mi.

About Bright Pine Behavioral Health 

Bright Pine Behavioral Health is a trusted provider of counseling and psychological testing services dedicated to helping individuals achieve their personal, academic, and professional goals. With a commitment to excellence and client-centered care, our team of licensed psychologists and mental health professionals offers a wide range of assessment and therapy services tailored to meet the unique needs of each client.

Media Contact
Company Name: Bright Pine Behavioral Health
Contact Person: Support
Email: Send Email
Phone: 248-455-6619
Address:1739 W BIG BEAVER
City: Troy
State: MI 48084
Country: United States
Website: https://www.brightpinepsychology.com/troy/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Unlocking Potential: Psychological Testing Services Now Available in Troy, MI

Predictive Power Unleashed: H.L. Howard’s Tarot Forecast Triumphs in Fairfield Ludlow HS House Game

“H.L. Howard, who first encountered the mystical world of tarot during his own personal quests, described the prediction as “Shockingly Accurate,” a testament to the unseen forces that he believes guide our destinies.”
Author and Mystic H.L. Howard Predicts Shocking Outcome, Reveals Plans for Groundbreaking New Book on “Zodiac-Based Emotional Intelligence”

Fairfield, CT – April 22, 2024 – In an extraordinary display of predictive prowess, author and tarot interpreter H.L. Howard accurately forecasted the victory of Warner House at the Fairfield Ludlow High School house game held on March 28, 2024. This announcement made three days prior to the event on March 25, marks Howard’s first public venture into real-time tarot predictions, underscoring a significant moment in both his career and the broader field of mystical studies.

H.L. Howard, who first encountered the mystical world of tarot during his own personal quests, described the prediction as “Shockingly Accurate,” a testament to the unseen forces that he believes guide our destinies. Inspired by his experiences and the teachings in his debut book, “A Journey Must Be Taken – Playlist,” Howard continues to explore how these “invisible hands” can influence and enhance human endeavors.

This successful prediction showcased Howard’s unique talent and bolstered his philosophy that the tarot can be a powerful tool for making sense of and navigating future events. Enthused by this success, Howard has announced his plans to pen a revolutionary new book titled “Zodiac Based Emotional Intelligence.” This forthcoming work aims to synthesize years of research into the application of zodiac-driven insights to everyday life, with potential implications as far-reaching as programming humanoid robots with personality traits based on astrological emotional intelligence.

As the world increasingly embraces alternative wisdom, Howard’s work promises to usher in a new era where the esoteric and the technological converge, offering fresh perspectives on personal and collective growth. With his upcoming projects, Howard is set to redefine the boundaries of how we understand the interplay between the cosmos and the course of human events.

For more information, interviews, or inquiries, please contact:

Name: H.L.Howard

Email: support@themelvilleverse.com

Website: https://www.hlhoward.com

About H.L. Howard

H.L. Howard is an accomplished author and expert in tarot interpretation whose work explores the interface between mystical forces and practical applications. His groundbreaking insights into how invisible guidance can be harnessed for personal success have made him a sought-after figure in the realms of spirituality and self-help.

For more information for this prediction, please visit:

https://youtu.be/c9X-kupThCw?si=GLDVggpw-n_EbJg6

Don’t miss out on this extraordinary literary journey. Get your copy of A Journey Must Be Taken – Playlist today and embark on a love story that transcends boundaries and defies destiny.

For more information, please visit:

Amazon: https://www.amazon.com/Journey-Must-Be-Taken-Playlist-ebook/dp/B0BRP35WF7

B&N: https://www.barnesandnoble.com/w/a-journey-must-be-taken-h-l-howard/1142964836?ean=9798987097618

Website: https://www.themelvilleverse.com/

Email: support@theMelvilleVerse.com

City: Fairfield

State: Connecticut

Phone: 475-345-4518

Media Contact
Company Name: AAPH
Contact Person: H.L. Howard
Email: Send Email
Country: United States
Website: https://www.hlhoward.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Predictive Power Unleashed: H.L. Howard\’s Tarot Forecast Triumphs in Fairfield Ludlow HS House Game

Atopic Dermatitis Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032),States DelveInsight | Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharma, Kyowa Kirn

The Atopic Dermatitis Market size was valued approximately USD 17 billion in 2023 and the report offers an in-depth understanding of the Atopic Dermatitis, historical and forecasted epidemiology as well as the Atopic Dermatitis market trends in the 7MM.

Atopic Dermatitis Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharma, SCM Lifescience, Sun Pharma, Brickell Biotech Inc,, AstraZeneca, Kyowa Kirin, UCB Biopharma

DelveInsight’s “Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Atopic Dermatitis, historical and forecasted epidemiology as well as the Atopic Dermatitis market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Atopic Dermatitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Atopic Dermatitis Market Forecast

 

Some of the key facts of the Atopic Dermatitis Market Report: 

  • The Atopic Dermatitis market size was valued approximately USD 17 billion in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
  • In 2023, Japan contributed around USD 1,700 million to the market size, with anticipated growth expected during the forecast period (2024–2034).
  • In March 2024, Sanofi has released promising results from the second phase of a study involving the OX40 antibody amlitelimab, demonstrating sustained improvement in managing symptoms of moderate to severe atopic dermatitis in previously treated patients. In the latter part of the STREAM-AD trial, patients who initially responded to amlitelimab were randomly assigned to either continue treatment or discontinue it for 28 weeks. Both groups showed consistently high responder rates for measures such as Eczema Area and Severity Index (EASI-75) and/or Investigator Global Assessment (IGA 0/1). Notably, 69.2% of patients who continued treatment and/or withdrew maintained IGA 0/1 and/or EASI-75 response, compared to 58.8% in the withdrawal group.
  • In Febuary 2024, Bio-Thera Solutions, a pharmaceutical firm headquartered in China, has progressed its monoclonal antibody BAT6026 into a Phase Ia/IIb clinical trial targeting patients with atopic dermatitis. The trial, identified as NCT06094179, has administered its initial dose to a patient and seeks to recruit 126 individuals with atopic dermatitis who have exhibited poor responses to prior topical treatments or were unable to utilize them.
  • In December 2023, InnoCare Pharma, a biopharmaceutical firm situated in China, has announced favorable top-line outcomes from the Phase II clinical study of ICP-332 for addressing atopic dermatitis. The Phase II trial, known as NCT05702268, was randomized, double-blind, and placebo-controlled, examining the safety, effectiveness, and pharmacokinetics of ICP-332 in 75 participants diagnosed with moderate-to-severe atopic dermatitis.
  • In December 2023, Technoderma Medicines, a biopharmaceutical firm based in China, has completed a Phase I clinical trial evaluating TDM-180935 topical ointment for managing atopic dermatitis. The randomized, double-blind trial assessed the tolerability, safety, and pharmacokinetics of TDM-180935 in healthy male subjects. Participants were divided into single-dose and multidose escalation cohorts for analysis.
  • In August 2023, Minghui Pharmaceutical has initiated enrollment for the Phase III clinical trial of its experimental MH004 Cream, designed to address mild to moderate atopic dermatitis (AD). This placebo-controlled, double-blind, randomized study aims to evaluate the efficacy and safety of MH004, a topical cream formulated with a pan-JAK inhibitor, across a broader population affected by the condition.
  • In 2023, there were approximately 53,348,000 diagnosed cases of atopic dermatitis across the 7MM, and it is anticipated that this number will rise in the forecast period from 2024 to 2034.
  • In 2023, there were approximately 72,435,000 prevalent cases of atopic dermatitis across the 7MM, and it is projected that these numbers will increase during the forecast period from 2024 to 2034.
  • In 2023, the total diagnosed cases of atopic dermatitis were approximately 23,481,000 for males and about 29,866,000 for females across the 7MM.
  • Key Atopic Dermatitis Companies: Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc,, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, Vanda Pharmaceuticals, Kyowa Kirin, Sanofi, KeyMed Biosciences, Asana BioSciences, Bristol-Myers Squibb, RAPT Therapeutics, Allakos, Novartis, BioMimetix, Shanghai Hengrui Pharmaceutical Co, Connect Biopharma, Pfizer, and others
  • Key Atopic Dermatitis Therapies: Bermekimab, FB825, Lebrikizumab, Nemolizumab, B244, Ruxolitinib, Difelikefalin, Roflumilast, Rocatinlimab, Tapinarof, KAPRUVIA/KORSUVA (difelikefalin), Etrasimod, BMX-010, and others
  • The Atopic Dermatitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Atopic Dermatitis pipeline products will significantly revolutionize the Atopic Dermatitis market dynamics.

 

Atopic Dermatitis Overview

Atopic dermatitis, often referred to as eczema, is a chronic inflammatory skin condition characterized by itchy, dry, red, and inflamed skin. It commonly affects areas where the skin flexes, such as inside the elbows, behind the knees, and on the face, neck, and hands. Atopic dermatitis is believed to result from a combination of genetic, immune system, and environmental factors. It often begins in infancy or childhood and may continue into adulthood.

 

Get a Free sample for the Atopic Dermatitis Market Report:

https://www.delveinsight.com/report-store/atopic-dermatitis-market

 

Atopic Dermatitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Atopic Dermatitis Epidemiology Segmentation:

The Atopic Dermatitis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Atopic Dermatitis
  • Prevalent Cases of Atopic Dermatitis by severity
  • Gender-specific Prevalence of Atopic Dermatitis
  • Diagnosed Cases of Episodic and Chronic Atopic Dermatitis

 

Download the report to understand which factors are driving Atopic Dermatitis epidemiology trends @ Atopic Dermatitis Epidemiology Forecast

 

Atopic Dermatitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Atopic Dermatitis market or expected to get launched during the study period. The analysis covers Atopic Dermatitis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Atopic Dermatitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Atopic Dermatitis Therapies and Key Companies

  • Bermekimab: Janssen Pharmaceutical
  • FB825: Oneness Biotech
  • Lebrikizumab: Eli Lily
  • Nemolizumab: Galderma
  • B244: AOBiome
  • Ruxolitinib: Incyte
  • Difelikefalin: Cara Therapeutics
  • Roflumilast: Arcutis Biotherapeutics
  • Rocatinlimab: Amgen/Kyowa Kirin
  • Tapinarof: Dermavant Sciences
  • KAPRUVIA/KORSUVA (difelikefalin): Cara Therapeutics
  • Etrasimod: Pfizer/Arena pharmaceuticals
  • BMX-010: BioMimetix

 

Discover more about therapies set to grab major Atopic Dermatitis market share @ Atopic Dermatitis Treatment Market 

 

Atopic Dermatitis Market Drivers

  • Rising prevalence of Atopic Dermatitis
  • Escalating expenditure on healthcare
  • Approvals of JAK inhibitors
  • Potential Emerging Therapies for Atopic Dermatitis and pruritus
  • Increasing awareness about the condition

 

Atopic Dermatitis Market Barriers

  • Over-the-counter medications
  • Outdated treatment recommendations
  • Poor prognosis and treatment adherence
  • Lack of timely diagnosis
  • Management of Atopic Dermatitis in the primary care setting

 

Scope of the Atopic Dermatitis Market Report

  • Study Period: 2020–2034
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Atopic Dermatitis Companies: Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc,, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, Vanda Pharmaceuticals, Kyowa Kirin, Sanofi, KeyMed Biosciences, Asana BioSciences, Bristol-Myers Squibb, RAPT Therapeutics, Allakos, Novartis, BioMimetix, Shanghai Hengrui Pharmaceutical Co, Connect Biopharma, Pfizer, and others
  • Key Atopic Dermatitis Therapies: Bermekimab, FB825, Lebrikizumab, Nemolizumab, B244, Ruxolitinib, Difelikefalin, Roflumilast, Rocatinlimab, Tapinarof, KAPRUVIA/KORSUVA (difelikefalin), Etrasimod, BMX-010, and others
  • Atopic Dermatitis Therapeutic Assessment: Atopic Dermatitis current marketed and Atopic Dermatitis emerging therapies
  • Atopic Dermatitis Market Dynamics: Atopic Dermatitis market drivers and Atopic Dermatitis market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Atopic Dermatitis Unmet Needs, KOL’s views, Analyst’s views, Atopic Dermatitis Market Access and Reimbursement 

 

To know more about Atopic Dermatitis companies working in the treatment market, visit @ Atopic Dermatitis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Atopic Dermatitis Market Report Introduction

2. Executive Summary for Atopic Dermatitis

3. SWOT analysis of Atopic Dermatitis

4. Atopic Dermatitis Patient Share (%) Overview at a Glance

5. Atopic Dermatitis Market Overview at a Glance

6. Atopic Dermatitis Disease Background and Overview

7. Atopic Dermatitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Atopic Dermatitis 

9. Atopic Dermatitis Current Treatment and Medical Practices

10. Atopic Dermatitis Unmet Needs

11. Atopic Dermatitis Emerging Therapies

12. Atopic Dermatitis Market Outlook

13. Country-Wise Atopic Dermatitis Market Analysis (2020–2034)

14. Atopic Dermatitis Market Access and Reimbursement of Therapies

15. Atopic Dermatitis Market Drivers

16. Atopic Dermatitis Market Barriers

17.  Atopic Dermatitis Appendix

18. Atopic Dermatitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Atopic Dermatitis Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032),States DelveInsight | Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharma, Kyowa Kirn

Basal Cell Carcinoma Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | AiVivA Biopharma, Sirnaomics, Pellepharm/ SolGel Technologies, Mediwound

The Basal Cell Carcinoma Market Forecast-2032 report offers an in-depth understanding of the Basal Cell Carcinoma, historical and forecasted epidemiology as well as the Basal Cell Carcinoma market trends in the 7MM.

DelveInsight’s “Basal Cell Carcinoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Basal Cell Carcinoma, historical and forecasted epidemiology as well as the Basal Cell Carcinoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Basal Cell Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Basal Cell Carcinoma Market Forecast

 

Some of the key facts of the Basal Cell Carcinoma Market Report: 

  • The Basal Cell Carcinoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • Skin cancer is the most prevalent cancer in the United States, according to the American Cancer Society (ACS), with basal cell carcinoma (BCC) accounting for the majority of occurrences. According to the ACS, over 3.4 million people in the US receive an estimated 5.4 million diagnoses of basal and squamous cell skin malignancies each year, with BCCs accounting for about 80% of those cases
  • The most prevalent type of skin cancer worldwide, according to the European Skin Cancer Foundation, is basal cell carcinoma. About 50 to 80 new cases of basal cell carcinoma are reported annually per 100,000 people in Europe
  • The estimated annual incidence of Basal Cell Carcinoma in the United States is 4.3 million, according to information from insurance registries and official statistics
  • Key Basal Cell Carcinoma Companies: AiVivA Biopharma, Sirnaomics, Pellepharm/ SolGel Technologies, Mediwound, PellePharm, Inc., Medivir, Merck Sharp & Dohme LLC, Amarex Clinical Research, Sanofi, Hoffmann-La Roche, Bristol-Myers Squibb, Will-Pharma, Novartis, AiViva BioPharma, Inc., MediWound Ltd, Galderma R&D, Genentech, Inc., Peplin, MEDA Pharma, and others
  • Key Basal Cell Carcinoma Therapies: AIV001, STP705, Patidegib, MW005, Patidegib, Remetinostat, Vismodegib, STP705, cemiplimab, ERIVEDGE, Nivolumab, Sinecatechins 10%, LDE225, AIV001, EscharEx, Metvix® cream, Vismodegib, PEP005, Imiquimod, and others
  • The Basal Cell Carcinoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Basal Cell Carcinoma pipeline products will significantly revolutionize the Basal Cell Carcinoma market dynamics.

 

Basal Cell Carcinoma Overview

Basal cell carcinoma (BCC) is the most common form of skin cancer and the most frequently occurring form of all cancers. BCC mostly arises on sun-damaged skin and rarely develops on the mucous membranes or palms and soles. Basal cell carcinoma is usually a slow-growing tumor for which metastases are rare. Although rarely fatal, BCC can be highly destructive and disfigure local tissues when treatment is inadequate or delayed.

 

Get a Free sample for the Basal Cell Carcinoma Market Report 

https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market

 

Basal Cell Carcinoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Basal Cell Carcinoma Epidemiology Segmentation:

The Basal Cell Carcinoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Basal Cell Carcinoma
  • Prevalent Cases of Basal Cell Carcinoma by severity
  • Gender-specific Prevalence of Basal Cell Carcinoma
  • Diagnosed Cases of Episodic and Chronic Basal Cell Carcinoma

 

Download the report to understand which factors are driving Basal Cell Carcinoma epidemiology trends @ Basal Cell Carcinoma Epidemiology Forecast

 

Basal Cell Carcinoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Basal Cell Carcinoma market or expected to get launched during the study period. The analysis covers Basal Cell Carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Basal Cell Carcinoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Basal Cell Carcinoma Therapies and Key Companies

  • AIV001: AiVivA Biopharma
  • STP705: Sirnaomics
  • Patidegib: Pellepharm/ SolGel Technologies
  • MW005: Mediwound
  • Patidegib: PellePharm, Inc.
  • Remetinostat: Medivir
  • Vismodegib: Merck Sharp & Dohme LLC
  • STP705: Amarex Clinical Research
  • cemiplimab: Sanofi
  • ERIVEDGE: Hoffmann-La Roche
  • Nivolumab: Bristol-Myers Squibb
  • Sinecatechins 10%: Will-Pharma
  • LDE225: Novartis
  • AIV001: AiViva BioPharma, Inc.
  • EscharEx: MediWound Ltd
  • Metvix® cream: Galderma R&D
  • Vismodegib: Genentech, Inc.
  • PEP005: Peplin
  • Imiquimod: MEDA Pharma

 

Discover more about therapies set to grab major Basal Cell Carcinoma market share @ Basal Cell Carcinoma Treatment Market 

 

Basal Cell Carcinoma Market Drivers

  • Rise in various environment factors, which leads to more UV exposure and increasing geriatric population who are more susceptible to skin disease.

 

Basal Cell Carcinoma Market Barriers

  • Constant research and well defined clinical trials may help in identifying potential novel treatments and improve outcomes for basal cell carcinoma patients, potential for premium pricing of emerging therapies by showing an edge over current therapies

 

Scope of the Basal Cell Carcinoma Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Basal Cell Carcinoma Companies: AiVivA Biopharma, Sirnaomics, Pellepharm/ SolGel Technologies, Mediwound, PellePharm, Inc., Medivir, Merck Sharp & Dohme LLC, Amarex Clinical Research, Sanofi, Hoffmann-La Roche, Bristol-Myers Squibb, Will-Pharma, Novartis, AiViva BioPharma, Inc., MediWound Ltd, Galderma R&D, Genentech, Inc., Peplin, MEDA Pharma, and others
  • Key Basal Cell Carcinoma Therapies: AIV001, STP705, Patidegib, MW005, Patidegib, Remetinostat, Vismodegib, STP705, cemiplimab, ERIVEDGE, Nivolumab, Sinecatechins 10%, LDE225, AIV001, EscharEx, Metvix® cream, Vismodegib, PEP005, Imiquimod, and others
  • Basal Cell Carcinoma Therapeutic Assessment: Basal Cell Carcinoma current marketed and Basal Cell Carcinoma emerging therapies
  • Basal Cell Carcinoma Market Dynamics: Basal Cell Carcinoma market drivers and Basal Cell Carcinoma market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Basal Cell Carcinoma Unmet Needs, KOL’s views, Analyst’s views, Basal Cell Carcinoma Market Access and Reimbursement 

 

To know more about Basal Cell Carcinoma companies working in the treatment market, visit @ Basal Cell Carcinoma Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Basal Cell Carcinoma Market Report Introduction

2. Executive Summary for Basal Cell Carcinoma

3. SWOT analysis of Basal Cell Carcinoma

4. Basal Cell Carcinoma Patient Share (%) Overview at a Glance

5. Basal Cell Carcinoma Market Overview at a Glance

6. Basal Cell Carcinoma Disease Background and Overview

7. Basal Cell Carcinoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Basal Cell Carcinoma 

9. Basal Cell Carcinoma Current Treatment and Medical Practices

10. Basal Cell Carcinoma Unmet Needs

11. Basal Cell Carcinoma Emerging Therapies

12. Basal Cell Carcinoma Market Outlook

13. Country-Wise Basal Cell Carcinoma Market Analysis (2019–2032)

14. Basal Cell Carcinoma Market Access and Reimbursement of Therapies

15. Basal Cell Carcinoma Market Drivers

16. Basal Cell Carcinoma Market Barriers

17.  Basal Cell Carcinoma Appendix

18. Basal Cell Carcinoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Basal Cell Carcinoma Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | AiVivA Biopharma, Sirnaomics, Pellepharm/ SolGel Technologies, Mediwound

Gratitude Lodge Celebrates Alcohol Awareness Month

April is alcohol awareness month and Gratitude Lodge wants to acknowledge the importance of bringing awareness to alcohol use disorder.

It is estimated that there are more than 178,00 alcohol-related deaths each year. There are also more than 200 diseases and injury-related conditions that are caused by alcohol misuse. Bringing awareness to alcohol use disorder can prevent death and allow people to live a life free of addiction.

To learn more about alcohol use disorder, people can visit www.gratitudelodge.com or call (949) 919-6195 to learn more and look into treatment options.

Alcohol use disorder affects one’s life as well as their loved ones. It can lead to issues with one’s physical and mental health, relationships, work, and finances. Treatment is still heavily stigmatized, however, know that alcoholism is not a choice and is best treated in a professional setting due to the dangerous nature of alcohol withdrawal. It can consist of medicated-assisted treatment, as well as various holistic therapies.

Alcohol use disorder is when regular or heavy drinking creates a change in one’s brain chemistry leading to increased tolerance which can develop into alcohol addiction. Some of the common causes for alcohol addiction include genetics, environmental factors, mental health conditions, social factors, and trauma. If one finds themselves unable to reduce alcohol intake, exceeding intended consumption, experiencing withdrawal symptoms, or experiencing issues with personal and professional life due to alcohol use; they may be experiencing alcohol use disorder.

This month Gratitude Lodge encourages readers to learn the signs and symptoms of alcohol use disorder to prevent or treat addiction before it’s too late.

Gratitude Lodge is a substance abuse treatment center in Southern California, including rehabs in Long Beach and Newport Beach. It offers various evidence-based treatment methods with an expert staff, providing a supportive and peaceful environment to treat addiction. Gratitude Lodge works to ensure that all clients get the help they need and deserve to fight back against addiction and live a healthy lifestyle filled with gratitude, helping them appreciate each and every day.

Media Contact
Company Name: Gratitude Lodge
Contact Person: Elisabeth Williams
Email: Send Email
Country: United States
Website: https://www.gratitudelodge.com/

Recommend Introduces Next-Generation Product Discovery Platform: “The Future of Shopping Lies in Personalization”

Recommend serves as a product discovery platform, offering personalized online shopping experiences and contextual product presentations. As e-commerce evolves from a transactional to a discovery-oriented model, Recommend aims to streamline shopping decisions for users, guiding them to seamlessly discover the products they seek.

Recommend has unveiled a next-generation AI product discovery platform. Named Recommend, the platform allows users to discover personalized shopping recommendations, explore relevant products across various categories, and see which products their friends recommend and use.

Recommend is available in 9 markets including the United Kingdom and the United States. On both the platform and mobile applications for iOS and Android, users can discover products across nearly 20 categories, ranging from clothing and beauty products to household appliances and sports equipment.

“At Recommend, the emphasis is on building the content around the products and personalization. That’s why, alongside a selection of top brands and products, we provide our users with concise contextual information that answers the question – what is the context of this product selection?,” explained Ivan Andabak, Co-founder of Recommend.

How To Deal With Information Overload?

It’s often said that in the past, the issue was the lack of choices, but ironically, the solution—more choices—has become the problem.

“The number of choices we face daily is enormous, especially when it comes to deciding what we want or need to buy. Information overload further complicates decision-making. The real challenge lies in determining how to choose precisely what we need,” emphasizes Andabak.

The Contemporary E-Commerce Landscape

The e-commerce landscape is undergoing a period of change. Once, online shopping was transactional, but now it’s discovery-driven.

“The first generation of online shoppers searched for a specific product in a specific variation, such as jeans size 27/30. Jeans were then purchased from online stores with a wide range of products, with jeans being just one of them. The second generation of e-commerce is characterized by specialization. Customers visited specialized stores. They didn’t have a specific jeans model in mind, but they wanted to find the perfect pair of jeans,” explains the co-founder of Recommend.

Finally, the third generation of e-commerce brings a focus on individual experience: “The key verb becomes ‘to discover.’ Alongside finding the right pair of jeans, it’s about experiencing the product. Shopping is no longer just a means to enable life to happen. The experience of shopping and discovering new products has become an integral part of life. And in doing so – precisely because of the information overload – personalization plays an increasingly important role.”

The Power of Personalization

Andabak underlines that every person has a unique set of needs, expectations, and tastes: “Without personalization, it’s impossible to create meaningful content and provide a relevant shopping experience. Offering winter tires on sale to someone who doesn’t own a car would be pointless.”

“Besides that, personalization is important for combating the internet’s information overload. Discovering relevant products in a contextual environment, easy browsing, and simple navigation through the catalog enables a smooth shopping experience that seamlessly integrates into everyday life,” clarified the Recommend’s co-founder.

Jobs-To-Be-Done in Online Shopping

Recommend is a personalized product discovery platform where various products are presented in a jobs-to-be-done framework. Jobs-to-be-done is based on the assumption that people hire products or services to accomplish a specific task or to satisfy a particular need.

“A person buying a drill doesn’t actually want a hole, but rather a shelf for books on the wall. The hole and the drill are just means to an end as the framework states”, explained Andabak.

“That’s precisely why we decided to approach products within this framework. Every piece of content on Recommend answers the questions: what problem does this product solve for me? what do I gain from it? how will my life become better because of this product? In addition to our original content, these questions are also addressed by user-generated content on Recommend, as well as content from content creators, experts in various fields”, concluded the co-founder of Recommend.

Conclusion

Recommend is a product discovery platform that provides a personalized approach to online shopping and presents products in context. In the e-commerce landscape, which has transitioned from transactional to a product discovery experience, Recommend’s idea is to facilitate shopping decisions for its users, help them discover new products, and make shopping fun.

Media Contact
Company Name: Recommend
Contact Person: Ivan Andabak
Email: Send Email
Country: United States
Website: https://www.recommend.co/en-US